Synthetic Biologics, Inc(SYN): For the most recent quarter end, Synthetic Biologics, Inc reported Annual Earnings of $-0.09. Based on the filings, last years Annual Earnings was, $-0.54. For the most recent quarter end, SYN reported a surprise Earnings per Share of 0% . The consensus estimate for current quarter is $-0.09 and for the current fiscal year, the estimate is $-0.36. For the Next fiscal year, the estimate is $-0.37 based on the consensus. Rockville based Synthetic Biologics, Inc Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 09, 2017.
Synthetic Biologics, Inc has received $-0.09 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.09 while the top line estimate is $-0.08 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 29.17%. According to the corporate earnings calendar, Synthetic Biologics, Inc will release next earnings on Mar 09, 2017 with an estimated EPS consensus of $-0.09. Based on the consensus of stock financial advisors the stock has a price target of $5.33. Current year estimate on EPS consensus is $-0.36.
For Dividend Investing Stock Market Traders Synthetic Biologics, Inc has a Dividend Yield of 0% with an Annual Dividend of $0.
Synthetic Biologics, Inc (NYSEMKT:SYN) witnessed a decline in the market cap on Wednesday as its shares dropped 2.62% or 0.0208 points. After the session commenced at $0.8, the stock reached the higher end at $0.8055 while it hit a low of $0.7501. With the volume soaring to 865,352 shares, the last trade was called at $0.7726. The company has a 52-week high of $2.735. The company has a market cap of $91 million and there are 117,172,714 shares in outstanding. The 52-week low of the share price is $0.7349.
Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan.